Method and use of deferiprone for the treatment and / or prevention of Friedreich's ataxia resulting from poor intracellular treatment of iron

• 收藏
• 分享

专利权人:

アポテックス;アポテックス テクノロジーズ インク.;テクノロジーズ;インク．

发明人:

ムニチ，アーノルド,スピーノ，マイケル,キャバンチク，イオアブ,ムニチ,アーノルド,スピーノ,マイケル,キャバンチク,イオアブ

申请号：

JP2008555581

公开号：

JP5730466B2

申请日:

2007.02.21

申请国别(地区):

JP

年份:

2015

代理人:

摘要：

A therapeutically effective amount of deferiprone or deferasirox or physiologically acceptable salts thereof for the prevention, stabilization, treatment, or reversal of iron-induced FRDA disease in patients resulting from mitochondrial iron-induced damage to preferentially reduce the iron stores in the mitochondria. Also for the treatment of other conditions affecting the brain where a key element in the generation of the resultant pathology is the intracellular mishandling of iron.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/